Parabilis Medicines Email Format

Biotechnology ResearchMassachusetts, United States201-500 Employees

FogPharma is a biotechnology research company headquartered in Cambridge, Massachusetts, with 51-200 employees. It is described as clinical-stage and uses its Helicon discovery platform to engineer stabilized helical peptide therapeutics aimed at intracellular targets that have historically been difficult to drug. Its lead program, FOG-001, is a first-in-class β-catenin inhibitor that blocks TCF signaling and is in a Phase 1/2 study for colorectal cancer and other solid tumors. The company maintains a broader pipeline of first-in-class programs and modalities, including protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. In mid-2026 the entity, referred to as Parabilis Medicines (formerly FogPharma), completed a Nasdaq IPO and began trading, with reports of a market capitalization around $3.7 billion and an IPO raise of about $670 million.

Get verified Parabilis Medicines emails free

Company overview Employee directory